Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis;Diagnostische Genauigkeit von Anti-MCV- und Anti-CCP-Antikörpern bei rheumatoider Arthritis: Eine Metaanalyse

Zeitschrift fur Rheumatologie

Volumn 74, Issue 10, 2015, Pages 911-918

  Lee, Y H ^a   Bae, S C ^b   Song, G G ^a  

^a College of Medicine   (South Korea)

^b Hanyang University Medical Center   (South Korea)

Author keywords

Autoantibodies; Autoantigens; Autoimmune diseases; Biological marker; Early diagnosis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MUTATED CITRULLINATED VIMENTIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; VIMENTIN;

AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CONTROL; DISEASE PREDISPOSITION; HEREDITY; HUMAN; META ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ARTHRITIS, RHEUMATOID; BLOOD; FEMALE; IMMUNOLOGY; MALE; PREVALENCE; REPRODUCIBILITY; RISK FACTOR;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; FEMALE; HUMANS; MALE; PEPTIDES, CYCLIC; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VIMENTIN;

EID: 84949315001     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-015-1598-x     Document Type: Article

References (42)

1. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903–911
2. Lard LR, Visser H, Speyer I et al (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111(6):446–451
3. Dorner T, Egerer K, Feist E, Burmester GR (2004) Rheumatoid factor revisited. Curr Opin Rheumatol 16(3):246–253
4. Schellekens GA, Jong BA de, Hoogen FH van den et al (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101(1):273–281
5. Boekel MA van, Vossenaar ER, Hoogen FH van den, Venrooij WJ van (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4(2):87–93
6. Vossenaar ER, Zendman AJ, Venrooij WJ van, Pruijn GJ (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25(11):1106–1118
7. Schellekens GA, Visser H, Jong BA de et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43(1):155–163
8. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nat Cell Biol 5(1):59–63
9. Bang H, Egerer K, Gauliard A et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56(8):2503–2511
10. Vossenaar ER, Despres N, Lapointe E et al (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6(2):R142–R150
11. Hueber W, Hassfeld W, Smolen JS, Steiner G (1999) Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) 38(2):155–159
12. Luime JJ, Colin EM, Hazes JM, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69(2):337–344
13. Zhu T, Feng L (2013) Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients. Int J Rheum Dis 16(2):157–161
14. Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Alkaabi J (2012) Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated Peptide antibodies and rheumatoid factor in omani patients with rheumatoid arthritis. Int J Rheumatol 2012:285854
15. Damjanovska L, Thabet MM, Levarth EW et al (2010) Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 69(4):730–732
16. Mutlu N, Bicakcigil M, Tasan DA et al (2009) Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J Rheumatol 36(3):491–500
17. Mathsson L, Mullazehi M, Wick MC et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58(1):36–45
18. Diaz-Toscano ML, Olivas-Flores EM, Zavaleta-Muniz SA et al (2014) Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing. Biomed Res Int 2014:198198
19. El-Barbary AM, Kassem EM, El-Sergany MA et al (2011) Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. J Rheumatol 38(5):828–834
20. Liu X, Jia R, Zhao J, Li Z (2009) The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. J Rheumatol 36(6):1136–1142
21. Innala L, Kokkonen H, Eriksson C et al (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35(6):1002–1008
22. Soos L, Szekanecz Z, Szabo Z et al (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34(8):1658–1663
23. Nicaise Roland P, Grootenboer Mignot S, Bruns A et al (2008) Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 10(6):R142
24. Song JS, Park GB, Park AJ (2007) Comparison of anti-mutated citrullinated vimentin with anti-cyclic citrullinated peptide and rheumatoid factors for the diagnostic value of rheumatoid arthritis. Korean Rheum Assoc 14:235–241
25. Lee YH, Bae SC, Choi SJ et al (2011) Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 38(6):3643–3651
26. Lee YH, Rho YH, Choi SJ et al (2006) Association of TNF-alpha − 308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 27(2):157–161
27. Lee YH, Rho YH, Choi SJ et al (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27(9):827–833
28. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
29. Whiting P, Rutjes AW, Reitsma JB et al (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25
30. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558
31. Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315(7121):1533–1537
32. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
33. Lijmer JG, Bossuyt PM, Heisterkamp SH (2002) Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 21(11):1525–1537
34. Walter SD (2002) Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21(9):1237–1256
35. Zamora J, Abraira V, Muriel A et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31
36. Besada E, Nikolaisen C, Nossent JC (2011) Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis. Clin Exp Rheumatol 29(1):85–88
37. Dejaco C, Klotz W, Larcher H et al (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8(4):R119
38. Ursum J, Nielen MM, Schaardenburg DV et al (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10(1):R12
39. Wagner E, Skoumal M, Bayer P, Klaushofer K (2009) Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 29(11):1315–1321
40. Yousefghahari B, Alhooei S, Soleimani-amiri MJ, Guran A (2013) Comparison of sensitivity and specificity of anti-CCP and anti-MCV antibodies in an Iranian cohort of patients with rheumatoid arthritis. Caspian J Intern Med 4(3):702
41. Maraina CHC, Nurdayana AK, Rusni D, Azwany Y (2010) Diagnostic value of anti‐modified citrullinated vimentin in rheumatoid arthritis. Int J Rheum Dis 13(4):335–339
42. Bartoloni E, Alunno A, Bistoni O et al (2012) Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 11(11):815–820